Why the Sanofi and Translate Bio Vaccine Pact Is Win-Win

By Chris Lange Updated Jun 23, 1:14PM EDT · Published Jun 23, 10:07AM EDT

Follow 24/7 Wall St. on Google

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Why the Sanofi and Translate Bio Vaccine Pact Is Win-Win — © SergeyNivens / Getty Images

Sanofi S.A. (NASDAQ: SNY | SNY Price Prediction) and Translate Bio Inc. (NASDAQ: TBIO) are making waves in the fight against the novel coronavirus as the two have agreed to expand their existing 2018 collaboration and license agreement to develop messenger RNA (mRNA) vaccines for infectious diseases.

Under the collaboration, Translate Bio is using its mRNA platform to discover, design and manufacture vaccine candidates and Sanofi is providing its deep vaccine expertise to advance vaccine candidates into and through further development. At the same time, Translate Bio will transfer technology and processes to allow Sanofi Pasteur to develop and manufacture mRNA vaccines for infectious diseases.

As for the financials of this agreement, Translate Bio will receive a total upfront payment of $425 million, consisting of a $300 million cash payment and a private placement common stock investment of $125 million at $25.59 per share. That represents a 50% premium to the 20-day moving average.

Also, Translate Bio is eligible for potential future milestones and other payments up to $1.9 billion, including $450 million of milestones under the 2018 agreement. Approximately $360 million of the cash is expected over the next several years, inclusive of COVID-19 vaccine development milestones.

[nativounit]

Even more, Translate Bio is also eligible to receive tiered royalty payments based on worldwide sales of the developed vaccines. Sanofi will pay for all costs during the collaboration term.

What Sanofi gets out of this agreement is exclusive worldwide rights for the infectious disease vaccines developed.

Overall, not a bad deal for either side.

Translate Bio stock traded up about 60% to $25.99 on Tuesday, in a 52-week range of $6.80 to $26.50. The consensus price target is $20.33.

Sanofi was up fractionally at $52.75. It has a 52-week range of $6.80 to $26.50 and a consensus price target of $56.63.

[wallst_email_signup]

About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.